InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Atara Biotherapeutics, Inc.

ATRA Clue Score62
United States Fiscal year ends December CIK 0001604464
$9.48 +2.71% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $9.48 −44.00% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Operating income−81.2Net income−79.0Fiscal year 2017Operating income−121.5Net income−119.5Fiscal year 2018Operating income−237.1Net income−230.7Fiscal year 2019Operating income−295.7Net income−291.0Fiscal year 2020Operating income−309.1Net income−306.6EPS, diluted−4.15Fiscal year 2021Operating income−340.5Net income−340.1EPS, diluted−3.63Fiscal year 2022Revenue63.6Operating income−280.5Net income−228.3EPS, diluted−2.24Fiscal year 2023Revenue8.6 −86.5%Operating income−276.0Net income−276.1EPS, diluted−65.19Fiscal year 2024Revenue128.9 +1,404.0%Operating income−83.4Net income−85.4EPS, diluted−11.41Fiscal year 2025Revenue120.8 −6.3%Operating income35.9Net income32.7EPS, diluted2.57
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a n/a n/a 63.6 8.6 128.9 120.8
Growth −86.5% +1,404.0% −6.3%
Operating income −81.2 −121.5 −237.1 −295.7 −309.1 −340.5 −280.5 −276.0 −83.4 35.9
Net income −79.0 −119.5 −230.7 −291.0 −306.6 −340.1 −228.3 −276.1 −85.4 32.7
Growth
EPS, diluted n/a n/a n/a n/a −4.15 −3.63 −2.24 −65.19 −11.41 2.57

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Operating margin−441.2%Net margin−359.1%Free cash flow margin−432.0%Fiscal year 2023Operating margin−3,219.5%Net margin−3,220.9%Free cash flow margin−2,265.3%Fiscal year 2024Operating margin−64.7%Net margin−66.2%Free cash flow margin−53.5%Fiscal year 2025Operating margin29.7%Net margin27.1%Free cash flow margin−42.2%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a n/a −441.2% −3,219.5% −64.7% 29.7%
Net margin n/a n/a n/a n/a n/a n/a −359.1% −3,220.9% −66.2% 27.1%
Free cash flow margin n/a n/a n/a n/a n/a n/a −432.0% −2,265.3% −53.5% −42.2%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−60.0Capital expenditure−3.0Free cash flow−63.0Fiscal year 2017Operating cash flow−87.5Capital expenditure−20.2Free cash flow−107.7Fiscal year 2018Operating cash flow−179.8Capital expenditure−35.9Free cash flow−215.7Fiscal year 2019Operating cash flow−235.6Capital expenditure−5.7Free cash flow−241.4Fiscal year 2020Operating cash flow−180.8Capital expenditure−4.5Free cash flow−185.3Fiscal year 2021Operating cash flow−220.5Capital expenditure−10.6Free cash flow−231.1Fiscal year 2022Operating cash flow−270.4Capital expenditure−4.2Free cash flow−274.6Fiscal year 2023Operating cash flow−193.0Capital expenditure−1.2Free cash flow−194.2Fiscal year 2024Operating cash flow−68.7Capital expenditure−0.2Free cash flow−69.0Fiscal year 2025Operating cash flow−50.9Capital expenditure0.0Free cash flow−50.9
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −60.0 −87.5 −179.8 −235.6 −180.8 −220.5 −270.4 −193.0 −68.7 −50.9
Capital expenditure −3.0 −20.2 −35.9 −5.7 −4.5 −10.6 −4.2 −1.2 −0.2 0.0
Free cash flow −63.0 −107.7 −215.7 −241.4 −185.3 −231.1 −274.6 −194.2 −69.0 −50.9
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash48.0Shareholders’ equity253.7Fiscal year 2017Cash79.2Shareholders’ equity177.9Fiscal year 2018Cash60.7Shareholders’ equity339.2Fiscal year 2019Cash74.3Shareholders’ equity290.8Fiscal year 2020Cash200.4Shareholders’ equity462.3Fiscal year 2021Cash106.1Shareholders’ equity279.6Fiscal year 2022Cash92.9Shareholders’ equity126.6Fiscal year 2023Cash25.8Shareholders’ equity99.2Fiscal year 2024Cash25.0Shareholders’ equity−97.3Fiscal year 2025Cash8.5Shareholders’ equity−38.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 48.0 79.2 60.7 74.3 200.4 106.1 92.9 25.8 25.0 8.5
Shareholders’ equity 253.7 177.9 339.2 290.8 462.3 279.6 126.6 99.2 −97.3 −38.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
n/a n/a n/a n/a n/a n/a −441.2% −3,219.5% −64.7% 29.7%
n/a n/a n/a n/a n/a n/a −359.1% −3,220.7% −66.2% 27.1%
n/a n/a n/a n/a n/a n/a −359.1% −3,220.9% −66.2% 27.1%
n/a n/a n/a n/a n/a n/a −432.0% −2,265.3% −53.5% −42.2%
Spending
n/a n/a n/a n/a n/a n/a 428.7% 2,622.0% 117.5% 31.0%
n/a n/a n/a n/a n/a n/a 112.6% 593.8% 30.9% 21.7%
n/a n/a n/a n/a n/a n/a 6.6% 14.3% 0.2% 0.0%
n/a n/a n/a n/a n/a n/a n/a n/a n/a 0.1%
Returns
−31.2% −67.2% −68.0% −100.1% −66.3% −121.6% −180.3% −278.3% n/a n/a
−30.0% −54.9% −58.9% −84.8% −52.1% −72.7% −60.7% −166.8% −78.3% 161.5%
Balance and payout
3.9% 18.3% 13.5% 15.2% 21.4% 40.3% 66.4% 160.0% 189.2% 290.3%